Antibacterials: a dying trade
: Despite strong worldwide demand for effective antibacterial products, sustaining growth within this segment will become a challenging task for major pharmaceutical companies. Currently only six marketed drugs have sales of greater than $1 billion and by 2011, 12 out of 29 key products will face patent expiry. A relatively sparse R&D pipeline will do little to replace older products.